Under 10% of people that would benefit from obesity jabs such as Wegovy have access to them, states the World Health Organization as it releases its initial recommendations on the medications.
Considering over a billion individuals worldwide now obese, it is urging more widespread and fairer availability to these injectable treatments.
Per estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our latest guidance affirms that obesity is a long-term condition that can be treated with holistic and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key hurdles to broad availability to the jabs that can assist patients in reducing substantial weight, says the body.
Weight-Loss Drug Shortage
Despite the present most optimistic outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of eligible patients, as stated by the health organization.
The advice encourages governments and firms to widen access, through measures such as voluntary licensing.
Exclusive production rights on a key compound – the core component of a leading brand – is scheduled to end in a number of countries in 2026.
How Obesity Injections Work
The injections replicate a body's own hormone to slow digestion, suppress the appetite and boost the sense of being full so individuals reduce food intake.
Individuals commonly see weight reduction within a few weeks of starting on the weekly injections.
Research indicates people may put most of the weight back on within a year of discontinuing the drug, because their typical appetite come back.
To be above a healthy weight increases your likelihood for experiencing diseases, including type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects individuals in every country and was associated with millions of deaths worldwide in 2024, per the WHO.
